KOD

Kodiak Sciences' stock price has been significantly impacted by several events in the past six months, particularly a substantial surge, increasing by 171.56% over the last month and 595.47% over the last year. On September 28, 2026, the company announced positive topline results from its pivotal Phase 3 DAYBREAK study for Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501) in patients with wet age-related macular degeneration (wAMD), demonstrating non-inferiority in vision gains compared to aflibercept at year one, which led to a massive single-day stock surge of over 140% to 178%. Following these results, several analysts reacted favorably, reiterating or upgrading their ratings and significantly increasing price targets for Kodiak Sciences. In October 2026, Kodiak Sciences is scheduled to present clinical data across all three late-stage programs at the AAO 2026 meeting, including the first scientific presentation of Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted, Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy, and Phase 1b APEX data for KSI-101. On May 7, 2026, the company reported Q1 FY2026 results, including positive Phase 3 GLOW2 topline data for Zenkuda in diabetic retinopathy. As of Q2 2026, Kodiak reported a cash position of $125.9 million and a net loss of $65.6 million for the quarter, expecting its cash to fund operations into 2027, indicating a potential need for future funding. Insiders purchased approximately 1.94 million shares worth $157 million over the past 90 days, with insiders collectively owning 44.4% of the company, including a director acquiring 807,840 shares on September 28, 2026, for over $58 million, signaling strong internal conviction.